PCGF1

Summary

PCGF1 (polycomb group ring finger 1, HGNC:17615) is a protein-coding gene on chromosome 2p13.1, encoding Polycomb group RING finger protein 1 (Q9BSM1). Component of the Polycomb group (PcG) multiprotein BCOR complex, a complex required to maintain the transcriptionally repressive state of some genes, such as BCL6 and the cyclin-dependent kinase inhibitor, CDKN1A.

PCGF1 is a mammalian homolog of the Drosophila polycomb group genes, which act as transcriptional repressors to regulate anterior-posterior patterning in early embryonic development (Nunes et al., 2001 [PubMed 11287196]). See also PCGF2 (MIM 600346).

Source: NCBI Gene 84759 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 33 total
• MANE Select transcript: NM_032673

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17615
Approved symbol	PCGF1
Name	polycomb group ring finger 1
Location	2p13.1
Locus type	gene with protein product
Status	Approved
Aliases	NSPC1, RNF68, MGC10882
Ensembl gene	ENSG00000115289
Ensembl biotype	protein_coding
OMIM	610231
Entrez	84759

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 8 protein_coding, 4 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000233630, ENST00000463744, ENST00000465993, ENST00000475863, ENST00000480844, ENST00000489914, ENST00000496911, ENST00000877061, ENST00000913069, ENST00000913070, ENST00000913071, ENST00000913072, ENST00000913073, ENST00000948999

RefSeq mRNA: 1 — MANE Select: NM_032673 NM_032673

CCDS: CCDS1946

Canonical transcript exons

ENST00000233630 — 9 exons

Exon	Start	End
ENSE00000920831	74507576	74507695
ENSE00003494025	74505552	74505638
ENSE00003516406	74505043	74505190
ENSE00003538403	74505339	74505419
ENSE00003554787	74505952	74506057
ENSE00003559332	74506732	74506884
ENSE00003590667	74507042	74507147
ENSE00003599722	74506181	74506252
ENSE00003674192	74505737	74505770

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 98.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.3586 / max 89.6845, expressed in 1809 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
29225	8.9220	1785
29224	7.3846	1731
29223	1.0998	774
29222	0.9522	578

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	98.60	gold quality
secondary oocyte	CL:0000655	95.69	gold quality
granulocyte	CL:0000094	94.25	gold quality
lower esophagus mucosa	UBERON:0035834	94.24	gold quality
mucosa of transverse colon	UBERON:0004991	93.57	gold quality
right lobe of liver	UBERON:0001114	93.07	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.64	gold quality
metanephros cortex	UBERON:0010533	92.44	gold quality
cerebellar hemisphere	UBERON:0002245	92.18	gold quality
pituitary gland	UBERON:0000007	92.09	gold quality
cerebellar cortex	UBERON:0002129	92.09	gold quality
body of stomach	UBERON:0001161	91.92	gold quality
body of pancreas	UBERON:0001150	91.85	gold quality
right uterine tube	UBERON:0001302	91.56	gold quality
adenohypophysis	UBERON:0002196	91.56	gold quality
apex of heart	UBERON:0002098	91.29	gold quality
monocyte	CL:0000576	91.27	gold quality
mononuclear cell	CL:0000842	91.26	gold quality
left lobe of thyroid gland	UBERON:0001120	91.25	gold quality
right lobe of thyroid gland	UBERON:0001119	91.13	gold quality
leukocyte	CL:0000738	91.11	gold quality
transverse colon	UBERON:0001157	90.71	gold quality
cerebellum	UBERON:0002037	90.61	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.59	gold quality
right adrenal gland	UBERON:0001233	90.35	gold quality
thyroid gland	UBERON:0002046	90.32	gold quality
islet of Langerhans	UBERON:0000006	90.19	gold quality
left adrenal gland	UBERON:0001234	90.08	gold quality
left adrenal gland cortex	UBERON:0035825	90.03	gold quality
pancreas	UBERON:0001264	90.02	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.21
E-MTAB-4850	no	76.45

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
POU5F1

Upstream regulators (CollecTRI, top): BCL6, RUNX1

miRNA regulators (miRDB)

21 targeting PCGF1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-8089	97.74	66.21	1698
HSA-MIR-4667-5P	97.61	66.67	1683
HSA-MIR-1298-3P	94.05	64.84	620

Literature-anchored findings (GeneRIF, showing 9)

• polycomb has a role in stem cell fate and development of cancer (review) (PMID:15315754)
• knockdown of PCGF1 results in reduced expression of DPPA4 and other subunits of the variant PRC1 complex at both mRNA and protein levels. Thus, PCGF1 represents a physical and functional link between Polycomb function and pluripotency (PMID:26687479)
• these results demonstrate that NSPc1 promotes cancer stem cell self-renewal by repressing the synthesis of all-trans retinoic acid via targeting RDH16 and may provide novel targets for glioma treatment in the future. (PMID:28394339)
• The results of the present study demonstrated that miR320a inhibition decreased insulininduced KGN cell proliferation and apoptosis by targeting PCGF1. (PMID:28849208)
• Structure and Role of BCOR PUFD in Noncanonical PRC1 Assembly and Disease. (PMID:32628469)
• PCGF1 promotes epigenetic activation of stemness markers and colorectal cancer stem cell enrichment. (PMID:34148069)
• Cooperation between NSPc1 and DNA methylation represses HOXA11 expression and promotes apoptosis of trophoblast cells during preeclampsia. (PMID:36815373)
• MORC4 plays a tumor-promoting role in colorectal cancer via regulating PCGF1/CDKN1A axis in vitro and in vivo. (PMID:36932196)
• Balanced Epigenetic Regulation of MHC Class I Expression in Tumor Cells by the Histone Ubiquitin Modifiers BAP1 and PCGF1. (PMID:38088808)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pcgf1	ENSDARG00000001249
mus_musculus	Pcgf1	ENSMUSG00000069678
rattus_norvegicus	Pcgf1	ENSRNOG00000051433
drosophila_melanogaster	Psc	FBGN0005624
drosophila_melanogaster	Su(z)2	FBGN0265623

Paralogs (7): RNF2 (ENSG00000121481), PCGF6 (ENSG00000156374), BMI1 (ENSG00000168283), PCGF5 (ENSG00000180628), PCGF3 (ENSG00000185619), RING1 (ENSG00000204227), PCGF2 (ENSG00000277258)

Protein

Protein identifiers

Polycomb group RING finger protein 1 — Q9BSM1 (reviewed: Q9BSM1)

Alternative names: Nervous system Polycomb-1, RING finger protein 68

All UniProt accessions (1): Q9BSM1

UniProt curated annotations — full annotation on UniProt →

Function. Component of the Polycomb group (PcG) multiprotein BCOR complex, a complex required to maintain the transcriptionally repressive state of some genes, such as BCL6 and the cyclin-dependent kinase inhibitor, CDKN1A. Transcriptional repressor that may be targeted to the DNA by BCL6; this transcription repressor activity may be related to PKC signaling pathway. Represses CDKN1A expression by binding to its promoter, and this repression is dependent on the retinoic acid response element (RARE element). Promotes cell cycle progression and enhances cell proliferation as well. May have a positive role in tumor cell growth by down-regulating CDKN1A. Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A ‘Lys-119’, rendering chromatin heritably changed in its expressibility. Within the PRC1-like complex, regulates RNF2 ubiquitin ligase activity. Regulates the expression of DPPA4 and NANOG in the NT2 embryonic carcinoma cells.

Subunit / interactions. Interacts with BCORL1, forming heterodimers. The PCGF1-BCORL1 heterodimeric complex interacts with the KDM2B-SKP1 heterodimeric complex to form a homotetrameric polycomb repression complex 1 (PRC1.1). Component of the repressive BCOR complex containing a Polycomb group subcomplex at least composed of RYBP, RING1 and RNF2/RING2. Specifically interacts with BCOR, RING1 and RNF2/RING2. Component of a PRC1-like complex. Interacts with CBX6, CBX7 and CBX8. Interacts with DPPA4, NANOG, POU5F1 and RYBP.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BSM1-1	1	yes
Q9BSM1-3	2

RefSeq proteins (1): NP_116062* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR032443	RAWUL	Domain

Pfam: PF13923, PF16207

UniProt features (26 total): mutagenesis site 5, helix 4, strand 4, region of interest 3, turn 2, modified residue 2, cross-link 2, initiator methionine 1, chain 1, splice variant 1, zinc finger region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
4HPM	X-RAY DIFFRACTION	1.85
4HPL	X-RAY DIFFRACTION	2
8HCU	X-RAY DIFFRACTION	2.2
5JH5	X-RAY DIFFRACTION	2.55

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BSM1-F1	82.12	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 2, 3, 24, 88

Mutagenesis-validated functional residues (5):

Position	Phenotype
109	marked decrease of repressor activity. may be a kinase phosphorylation site.
191	abolishes interaction with bcor and bcorl1.
193	abolishes interaction with bcor and bcorl1.
195	abolishes repressor activity. may be a pkc phosphorylation site.
206	abolishes interaction with bcor and bcorl1.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 161 (showing top): MORF_RAGE, YAATNRNNNYNATT_UNKNOWN, TGCGCANK_UNKNOWN, MODULE_255, GCANCTGNY_MYOD_Q6, CGGAARNGGCNG_UNKNOWN, MORF_ATRX, MODULE_317, AREB6_01, PUJANA_CHEK2_PCC_NETWORK, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, CCANNAGRKGGC_UNKNOWN, MORF_PPP5C, MORF_FANCG, HEN1_01

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), chromatin remodeling (GO:0006338), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (4): zinc ion binding (GO:0008270), promoter-specific chromatin binding (GO:1990841), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), PcG protein complex (GO:0031519), PRC1 complex (GO:0035102)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
chromatin organization	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transition metal ion binding	1
chromatin binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
nuclear protein-containing complex	1
nuclear ubiquitin ligase complex	1
PcG protein complex	1

Protein interactions and networks

STRING

1072 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PCGF1	RING1	Q06587	997
PCGF1	RNF2	Q99496	997
PCGF1	RYBP	Q8N488	996
PCGF1	YAF2	Q8IY57	995
PCGF1	KDM2B	Q8NHM5	995
PCGF1	SKP1	P34991	972
PCGF1	CBX2	Q14781	914
PCGF1	BMI1	P35226	858
PCGF1	R4GMX3	R4GMX3	858
PCGF1	BCOR	Q6W2J9	855
PCGF1	PCGF2	P35227	847
PCGF1	PHC1	P78364	835
PCGF1	PCGF6	Q9BYE7	814
PCGF1	EZH2	Q15910	805
PCGF1	BCORL1	Q5H9F3	802

IntAct

127 interactions, top by confidence:

A	B	Type	Score
CBX8	BMI1	psi-mi:“MI:0914”(association)	0.970
RNF2	PCGF1	psi-mi:“MI:0915”(physical association)	0.950
PCGF1	RNF2	psi-mi:“MI:0915”(physical association)	0.950
CBX7	BMI1	psi-mi:“MI:0914”(association)	0.940
RYBP	CSNK2A2	psi-mi:“MI:0914”(association)	0.900
RING1	PCGF1	psi-mi:“MI:0915”(physical association)	0.890
PCGF1	RING1	psi-mi:“MI:0915”(physical association)	0.890
PCGF1	RING1	psi-mi:“MI:0914”(association)	0.890
PCGF1	BCOR	psi-mi:“MI:0914”(association)	0.880
PCGF1	BCOR	psi-mi:“MI:0915”(physical association)	0.880
RYBP	BMI1	psi-mi:“MI:0914”(association)	0.850
CBX8	PCGF1	psi-mi:“MI:0407”(direct interaction)	0.800
BCOR	KDM2B	psi-mi:“MI:0914”(association)	0.770
RYBP	E2F6	psi-mi:“MI:0914”(association)	0.740
RING1	CBX4	psi-mi:“MI:0914”(association)	0.730
RNF2	E2F6	psi-mi:“MI:0914”(association)	0.730
BCOR	SKP1	psi-mi:“MI:0914”(association)	0.730
NFIC	NFIB	psi-mi:“MI:2364”(proximity)	0.690
PCGF1	CBX7	psi-mi:“MI:0407”(direct interaction)	0.690
CBX8	BCOR	psi-mi:“MI:0914”(association)	0.660

BioGRID (372): PCGF1 (Affinity Capture-MS), PCGF1 (Affinity Capture-MS), PCGF1 (Affinity Capture-MS), PCGF1 (Affinity Capture-MS), PCGF1 (Affinity Capture-MS), PCGF1 (Two-hybrid), PCGF1 (Proximity Label-MS), PCGF1 (Proximity Label-MS), PCGF1 (Proximity Label-MS), PCGF1 (Affinity Capture-MS), PCGF1 (Affinity Capture-MS), PCGF1 (Affinity Capture-MS), PCGF1 (Affinity Capture-MS), RNF2 (Reconstituted Complex), PCGF1 (Biochemical Activity)

ESM2 similar proteins: A0JN86, A2AHJ4, A2APV2, A2AQW0, A9JRL3, B3DK16, O08874, O35099, P0CF52, P19447, P23798, P25916, P32866, P35226, P35227, P49135, Q07139, Q1JPS1, Q1RMT1, Q21029, Q28H21, Q2YDF9, Q32KX7, Q3UK78, Q4QR06, Q5R8L2, Q5RA62, Q5SDR3, Q5ZKK7, Q640D5, Q6DD21, Q6DLV9, Q6GN16, Q6RI45, Q6ZN16, Q7T3E6, Q7Z569, Q7ZYZ7, Q86SE9, Q8BPM2

Diamond homologs: A0JN86, B3DK16, P23798, P25916, P35226, P35227, Q07G17, Q0WX00, Q14527, Q1JPS1, Q28H21, Q2KJ29, Q2YDF9, Q32KX7, Q3KNV8, Q3UK78, Q4QR06, Q5R8L2, Q5SDR3, Q5XI70, Q640D5, Q6CJM4, Q6DLV9, Q7T3E6, Q7ZYZ7, Q86SE9, Q8BTQ0, Q8JIR0, Q8R023, Q91648, Q94AY3, Q99NA9, Q9BSM1, Q9BYE7, Q9FKW0, Q9LS86, Q9M9Y4, Q9TST0, O60106, Q19336

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	PCGF1	ubiquitination
PCGF1	“form complex”	“Noncanonical PRC1”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 110 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of DNA methylation proteins	5	45.4×	7e-06
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	11	44.7×	2e-13
Transcriptional Regulation by E2F6	6	23.7×	2e-05
SUMOylation of transcription cofactors	5	16.4×	6e-04
SUMOylation of RNA binding proteins	5	16.1×	6e-04
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	8	15.8×	6e-06
Deactivation of the beta-catenin transactivating complex	5	15.8×	6e-04
Regulation of PTEN gene transcription	6	14.5×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	5	18.4×	5e-04
cell fate commitment	6	16.3×	2e-04
forebrain development	5	16.1×	8e-04
inner ear morphogenesis	5	13.8×	2e-03
anatomical structure morphogenesis	9	11.5×	1e-05
chromatin remodeling	13	8.7×	7e-07
transcription by RNA polymerase II	13	8.4×	9e-07
gene expression	8	5.9×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1402 predictions. Top by Δscore:

Variant	Effect	Δscore
2:74505333:GCTTA:G	donor_loss	1.0000
2:74505334:CTTA:C	donor_loss	1.0000
2:74505335:TTA:T	donor_loss	1.0000
2:74505336:TACCT:T	donor_loss	1.0000
2:74505337:A:T	donor_loss	1.0000
2:74505415:TGCAC:T	acceptor_gain	1.0000
2:74505417:CAC:C	acceptor_gain	1.0000
2:74505418:AC:A	acceptor_gain	1.0000
2:74505419:CC:C	acceptor_gain	1.0000
2:74505420:C:CC	acceptor_gain	1.0000
2:74505421:T:C	acceptor_loss	1.0000
2:74505545:TACTC:T	donor_loss	1.0000
2:74505546:ACT:A	donor_loss	1.0000
2:74505547:CTCAC:C	donor_loss	1.0000
2:74505549:CACAT:C	donor_loss	1.0000
2:74505550:A:AC	donor_gain	1.0000
2:74505551:C:CC	donor_gain	1.0000
2:74505551:CATG:C	donor_gain	1.0000
2:74505646:C:CT	acceptor_gain	1.0000
2:74505647:A:T	acceptor_gain	1.0000
2:74505766:CAGAA:C	acceptor_gain	1.0000
2:74505768:GAA:G	acceptor_gain	1.0000
2:74505769:AA:A	acceptor_gain	1.0000
2:74505769:AAC:A	acceptor_loss	1.0000
2:74505771:C:CC	acceptor_gain	1.0000
2:74505771:CTGG:C	acceptor_loss	1.0000
2:74505772:T:A	acceptor_loss	1.0000
2:74505947:CTCAC:C	donor_loss	1.0000
2:74505948:TCA:T	donor_loss	1.0000
2:74505949:CA:C	donor_loss	1.0000

AlphaMissense

1715 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:74506227:G:C	F126L	1.000
2:74506227:G:T	F126L	1.000
2:74506228:A:G	F126S	1.000
2:74506229:A:G	F126L	1.000
2:74506240:C:G	R122P	1.000
2:74506752:A:G	L111P	1.000
2:74506770:T:G	Q105P	1.000
2:74506782:T:A	D101V	1.000
2:74506782:T:C	D101G	1.000
2:74506782:T:G	D101A	1.000
2:74506783:C:A	D101Y	1.000
2:74506783:C:G	D101H	1.000
2:74506791:A:G	L98P	1.000
2:74506791:A:T	L98H	1.000
2:74506803:G:T	P94Q	1.000
2:74506804:G:A	P94S	1.000
2:74506814:G:C	H90Q	1.000
2:74506814:G:T	H90Q	1.000
2:74506816:G:C	H90D	1.000
2:74506818:A:C	I89S	1.000
2:74506818:A:G	I89T	1.000
2:74506818:A:T	I89N	1.000
2:74506829:G:C	C85W	1.000
2:74506830:C:A	C85F	1.000
2:74506830:C:G	C85S	1.000
2:74506830:C:T	C85Y	1.000
2:74506831:A:G	C85R	1.000
2:74506831:A:T	C85S	1.000
2:74506836:G:T	P83H	1.000
2:74506837:G:A	P83S	1.000

dbSNP variants (sampled 300 via entrez): RS1000515517 (2:74504920 C>G,T), RS1002524278 (2:74507717 G>A), RS1003934282 (2:74508824 G>A), RS1004503452 (2:74507402 A>C,T), RS1004534799 (2:74507249 C>A), RS1005537525 (2:74507481 G>A), RS1005542139 (2:74508207 G>A), RS1006289098 (2:74508391 G>C), RS1009303636 (2:74504953 G>A,C), RS1009583993 (2:74504815 A>G), RS1010083798 (2:74504923 G>A), RS1010311174 (2:74506306 G>A), RS1011202811 (2:74507869 G>A), RS1011318866 (2:74507765 C>A,T), RS1012213285 (2:74509297 A>G)

Disease associations

OMIM: gene MIM:610231 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cyclosporine	increases expression	2
aristolochic acid I	increases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
ferrous chloride	increases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Sunitinib	increases expression	1
Atrazine	increases expression	1
Cannabidiol	decreases expression	1
Cycloheximide	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Niclosamide	increases expression	1
Phenobarbital	affects expression	1
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases expression	1
Vitamin E	increases expression	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	increases expression	1
Lactic Acid	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2G7	HAP1 PCGF1 (-)	Cancer cell line	Male
CVCL_F1QT	HyCyte HT-29 KO-hPCGF1	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.